BTIG Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX): "see the X-TOLE2 readout as having no readthrough"
Tweet Send to a Friend
BTIG analyst Kambiz Yazdi reiterated a Buy rating and $843.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
